Jill Wechsler

Jill Wechsler is Pharmaceutical Technology's Washington editor. She can be contacted by postal mail at 7715 Rocton Ave., Chevy Chase, MD 20815, by telephone at 301.656.4634, or by e-mail at jillw2@olg.com.

The heightened focus on risk raises concerns about delays in approving new drugs.

Strict enforcement, new rules, and organizational changes signal an activist tone.

Health crises generate support for new vaccines and treatments for diseases found in developing nations.

Pressure to reduce healthcare spending has put drug rebates, price cuts, and tax hikes on the table.

REMS to improve the safe use of opioids may lead to controls on other high-risk medicines.

The new commissioner of the US Food and Drug Administration is mapping plans for turning around an agency that has been demoralized, buffeted about in the press and has lost some of the trust of the American people.

Agency officials and manufacturers anticipate stricter enforcement of drug safety and quality.

Government funding is slated to boost comparative studies of prescription drugs.

President Obama's economic recovery plain includes goals such as reducing the number of uninsured citizens and improving the quality of healthcare.